. Author manuscript; available in PMC: 2019 Mar 8.

Published in final edited form as: Transpl Int. 2018 Jun 5;31(10):1164–1177. doi: 10.1111/tri.13273

Table 1.

Description of Study Groups and Treatment Regimens.

Study group	Baboon ID	Xeno-organs	Regimen
Study 1: Pilot study using available saved urine and kidney biopsy samples from three recipients of GalT-KO kidney
Pilot study	B289	Thymokidney	Anti-CD154 mAb-based regimen
	B314	Thymokidney	Anti-CD154 mAb/rituximab-based regimen
	B324	Kidney + BM
Study 2: Determine the effects of multiple doses of CTLA4-Ig treatment on the development of proteinuria following GalT-KO thymokidney transplantation in current (2013–2016) cases
CTLA-4Ig group (2015–2016)	B393	Thymokidney	Weekly doses of CTLA-4Ig + anti-CD154 mAb/rituximab-based
	B394		regimen
	14P5
Comp: non-CTLA4-Ig group (2013–2014)	B341	Thymokidney	Anti-CD154 mAb/rituximab-based regimen
	B358
	B363
	B366